TearClear Corp. is a clinical-stage ophthalmic pharmaceutical company founded in 2015 that develops a preservative-removing drug delivery platform: a chemical filter built into a conventional multi-dose eye-drop bottle that captures benzalkonium chloride (BAK) at the point of instillation, so the medication stays preserved in the bottle but reaches the ocular surface preservative-free. Its lead candidate TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal glaucoma trial, with TC-001 (timolol), TC-003 (brimonidine/timolol) and TC-004 (brimonidine) behind it. TearClear ships drug products and delivery hardware, not software: it operates no developer program and publishes no API, SDK or machine-readable contract, and its own corporate domain no longer resolves to a served website.
Tearclear is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Ophthalmology, Drug Delivery, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/tearclear: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: tearclear
name: Tearclear
description: 'TearClear Corp. is a clinical-stage ophthalmic pharmaceutical company founded in 2015 that develops a preservative-removing
drug delivery platform: a chemical filter built into a conventional multi-dose eye-drop bottle that captures benzalkonium
chloride (BAK) at the point of instillation, so the medication stays preserved in the bottle but reaches the ocular surface
preservative-free. Its lead candidate TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary
endpoints in the CLEAR Phase 3 pivotal glaucoma trial, with TC-001 (timolol), TC-003 (brimonidine/timolol) and TC-004 (brimonidine)
behind it. TearClear ships drug products and delivery hardware, not software: it operates no developer program and publishes
no API, SDK or machine-readable contract, and its own corporate domain no longer resolves to a served website.'
url: https://raw.githubusercontent.com/api-evangelist/tearclear/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-29'
modified: '2026-08-29'
tags:
- Company
- Pharmaceuticals
- Ophthalmology
- Drug Delivery
- Life Sciences
- Medical Devices
- Glaucoma
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: LinkedIn
url: https://www.linkedin.com/company/tearclear
- type: SecondaryMarketListing
url: https://www.hiive.com/securities/tearclear-stock
- type: DomainSecurity
url: security/tearclear-domain-security.yml
- type: LLMsTxt
url: llms/tearclear-llms.txt
x-website-note: 'No `Website` pointer is wired. The company''s registered domain, https://tearclear.com, returned HTTP 403
on 2026-08-29 over both HTTP and HTTPS with a browser User-Agent, under a TLS certificate for gcam1074.siteground.biz and
an `x-default-vhost: 1` response header — the domain is no longer provisioned as a virtual host on the SiteGround server
it points at, and the Internet Archive holds no successful capture after 2024-07-24. The previous `Website` pointer on this
profile was https://www.hiive.com/securities/tearclear-stock, a secondary-market trading venue listing rather than the company''s
own web presence; it has been retyped so its live 200 no longer stands in for a website the company does not serve.'
x-enrichment:
date: '2026-08-29'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: TearClear is a clinical-stage ophthalmic pharmaceutical company whose product is a BAK-removing eye-drop bottle
filter and the latanoprost/timolol/brimonidine drugs dispensed through it, so there is no software product to expose an
API on; separately, its own domain tearclear.com now answers 403 from an unprovisioned SiteGround default vhost, and no
api./developer./docs. subdomain resolves at all.
evidence:
- url: https://tearclear.com/
status: 403
- url: https://tearclear.com/openapi.json
status: 403
- url: https://tearclear.com/.well-known/agent-card.json
status: 403
- url: https://api.github.com/orgs/tearclear
status: 404
- url: https://www.linkedin.com/company/tearclear
status: 200
checked: '2026-08-29'